{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:02:53Z","timestamp":1770822173866,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.urology.2004.10.064","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T16:23:48Z","timestamp":1111076628000},"page":"549-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Evidence suggesting PSA cutpoint of 2.5 ng\/mL for prompting prostate biopsy: Review of 36,316 biopsies"],"prefix":"10.1016","volume":"65","author":[{"given":"Scott M.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina B.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillel","family":"Kahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2004.10.064_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0090-4295(03)00782-9","article-title":"Evidence of increased prostate cancer detection in men aged 50 to 59","volume":"62","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2004.10.064_bib2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2004.10.064_bib3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0022-5347(17)32396-0","article-title":"Cancer control and quality of life following anatomical radical retropubic prostatectomy","volume":"152","author":"Walsh","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2004.10.064_bib4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jama.1996.03540160031029","article-title":"Longitudinal screening for prostate cancer with prostate-specific antigen","volume":"276","author":"Smith","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2004.10.064_bib5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","article-title":"Serum prostate-specific antigen in a community-based population of healthy men","volume":"270","author":"Oesterling","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2004.10.064_bib6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199511233332107","article-title":"Screening for prostate cancer with prostate-specific antigen","volume":"333","author":"Woolf","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2004.10.064_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(99)00602-0","article-title":"Lowering PSA cutoffs to enhance detection of curable prostate cancer","volume":"55","author":"Catalona","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urology.2004.10.064_bib8","series-title":"Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection, version 1.2004","year":"2004"},{"key":"10.1016\/j.urology.2004.10.064_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa021659","article-title":"Effect of verification bias on screening for prostate cancer by measuring prostate-specific antigen","volume":"349","author":"Punglia","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2004.10.064_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.1997.03540420048028","article-title":"Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng\/ml and benign prostate examination","volume":"277","author":"Catalona","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2004.10.064_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0022-5347(05)66519-6","article-title":"The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng\/ml","volume":"165","author":"Babaian","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2004.10.064_bib12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-5347(05)67809-3","article-title":"Prostate cancer detection at low values of prostate-specific antigen (PSA)","volume":"163","author":"Schroder","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2004.10.064_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00005392-199904010-00399","article-title":"Total PSA cutoff of 2.5 correlates with favorable pathologic features of prostate cancer","volume":"161","author":"Krumholtz","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2004.10.064_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-4295(02)01875-7","article-title":"Prostate-specific antigen cutoff of 2.6 ng\/ml for prostate cancer screening is associated with favorable pathological features","volume":"60","author":"Krumholtz","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2004.10.064_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2004.10.064_bib16","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with prostate cancer-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2004.10.064_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","article-title":"Overdiagnosis due to prostate-specific antigen screening","volume":"94","author":"Etzioni","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2004.10.064_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead time and overdetection due to prostate-specific antigen screening","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2004.10.064_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ijc.10188","article-title":"Prostate cancer mortality reduction by screening","volume":"98","author":"de Koning","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2004.10.064_bib20","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1016\/S0197-2456(00)00097-0","article-title":"The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute","volume":"21","author":"Gohagan","year":"2000","journal-title":"Control Clin Trials"},{"issue":"suppl 4A","key":"10.1016\/j.urology.2004.10.064_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0090-4295(02)01693-X","article-title":"Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter","volume":"60","author":"Horninger","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2004.10.064_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/01.ju.0000092695.55705.dd","article-title":"Complexed prostate specific antigen improves specificity for prostate cancer detection","volume":"170","author":"Partin","year":"2003","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429504013214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429504013214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:42:10Z","timestamp":1758764530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429504013214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0090429504013214"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2004.10.064","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence suggesting PSA cutpoint of 2.5 ng\/mL for prompting prostate biopsy: Review of 36,316 biopsies","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2004.10.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}